AZN Stock Analysis: AstraZeneca | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 261.943m USD | 12M Return: 22.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 456M
EPS Trend: 95.1%
Qual. Beats: 0
Rev. Trend: 99.2%
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AstraZeneca PLC is a UK-based, mega-cap biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines across six major therapeutic areas: oncology, cardiovascular/renal/metabolism, respiratory and immunology, vaccines and immune therapies, and rare diseases. Its broad product portfolio spans established blockbusters (e.g., Tagrisso, Imfinzi, Farxiga) and newer launches (e.g., Imjudo, Datroway, Wainua), with global distribution to primary and specialty care physicians through local representative offices and distributors across the UK, Americas, Europe, Asia, Africa, and Australasia. The company is pursuing AI-driven drug development through strategic partnerships with Tempus/Pathos, CSPC Pharmaceutical Group, and Nucs AI, and is headquartered in Cambridge, UK, having been incorporated in 1992 and rebranded from Zeneca Group PLC in 1999.
As a pharmaceutical company in the highly regulated healthcare sector, AstraZeneca operates within a long-cycle R&D business model dependent on patent protection, clinical trial outcomes, and regulatory approvals. Diversification across multiple therapy areas and geographies helps mitigate the inherent risk of patent cliffs and single-drug trial failures common to the industry.
- Oncology revenue growth led by Tagrisso, Imfinzi, and Enhertu
- China sales decline on volume-based procurement pricing pressure
- Alexion rare disease margins expand as acquisition debt deleverages
| Net Income: 10.4b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.52 > 1.0 |
| NWC/Revenue: -4.89% < 20% (prev -5.44%; Δ 0.55% < -1%) |
| CFO/TA 0.13 > 3% & CFO 14.3b > Net Income 10.4b |
| Net Debt (28.1b) to EBITDA (20.5b): 1.37 < 3 |
| Current Ratio: 0.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.56b) vs 12m ago 100.0% < -2% |
| Gross Margin: 81.68% > 18% (prev 81.39%; Δ 0.29% > 0.5%) |
| Asset Turnover: 54.88% > 50% (prev 51.75%; Δ 3.13% > 0%) |
| Interest Coverage Ratio: 8.43 > 6 (EBIT TTM 14.7b / Interest Expense TTM 1.74b) |
| A: -0.03 (Total Current Assets 29.6b - Total Current Liabilities 32.6b) / Total Assets 114b |
| B: 0.08 (Retained Earnings 9.67b / Total Assets 114b) |
| C: 0.13 (EBIT TTM 14.7b / Avg Total Assets 110b) |
| D: 0.71 (Book Value of Equity 47.3b / Total Liabilities 66.6b) |
| Altman-Z'' = 1.75 = BBB |
| DSRI: 0.97 (Receivables 14.1b/13.2b, Revenue 60.4b/55.0b) |
| GMI: 1.00 (GM 81.39% / 81.68%) |
| AQI: 0.95 (AQ_t 0.61 / AQ_t-1 0.64) |
| SGI: 1.10 (Revenue 60.4b / 55.0b) |
| TATA: -0.03 (NI 10.4b - CFO 14.3b) / TA 114b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of July 23, 2026, the stock is trading at USD 169.73 with a total of 1,560,207 shares traded. Over the past week, the price has changed by +0.81%, over one month by -3.80%, over three months by -12.87% and over the past year by +22.52%.
Current recommended Stop Loss: 162.60 (which is 4.2% or 1.4 ATR below the current price).
AstraZeneca has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy AZN.
- StrongBuy: 7
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 214.4 | 26.3% |
P/E Trailing = 25.5136
P/E Forward = 16.4204
P/S = 4.3752
P/B = 5.5468
P/EG = 1.335
Revenue TTM = 60.4b USD
EBIT TTM = 14.7b USD
EBITDA TTM = 20.5b USD
Long Term Debt = 24.5b USD (from longTermDebt, last quarter)
Short Term Debt = 7.96b USD (from shortTermDebt, last quarter)
Debt = 35.8b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.89b
Net Debt = 28.1b USD (calculated: Debt 35.8b - CCE 7.67b)
Enterprise Value = 290b USD (262b + Debt 35.8b - CCE 7.67b)
Interest Coverage Ratio = 8.43 (Ebit TTM 14.7b / Interest Expense TTM 1.74b)
EV/FCF = 35.95x (Enterprise Value 290b / FCF TTM 8.07b)
FCF Yield = 2.78% (FCF TTM 8.07b / Enterprise Value 290b)
FCF Margin = 13.35% (FCF TTM 8.07b / Revenue TTM 60.4b)
Net Margin = 17.19% (Net Income TTM 10.4b / Revenue TTM 60.4b)
Gross Margin = 81.68% ((Revenue TTM 60.4b - Cost of Revenue TTM 11.1b) / Revenue TTM)
Gross Margin QoQ = 82.48% (prev 79.89%)
Tobins Q-Ratio = 2.54 (Enterprise Value 290b / Total Assets 114b)
Interest Expense / Debt = 4.85% (Interest Expense 1.74b / Debt 35.8b)
Taxrate = 19.52% (2.52b / 12.9b)
NOPAT = 11.8b (EBIT 14.7b * (1 - 19.52%))
Current Ratio = 0.91 (Total Current Assets 29.6b / Total Current Liabilities 32.6b)
Debt / Equity = 0.76 (Debt 35.8b / totalStockholderEquity, last quarter 47.3b)
Debt / EBITDA = 1.37 (Net Debt 28.1b / EBITDA 20.5b)
Debt / FCF = 3.49 (Net Debt 28.1b / FCF TTM 8.07b)
Total Stockholder Equity = 46.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.43% (Net Income 10.4b / Total Assets 114b)
RoE = 22.27% (Net Income TTM 10.4b / Total Stockholder Equity 46.7b)
RoCE = 20.61% (EBIT 14.7b / Capital Employed (Equity 46.7b + L.T.Debt 24.5b))
RoIC = 13.65% (NOPAT 11.8b / Invested Capital 86.4b)
WACC = 6.38% (E(262b)/V(298b) * Re(6.72%) + D(35.8b)/V(298b) * Rd(4.85%) * (1-Tc(0.20)))
Discount Rate = 6.72% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 26.07 | Cagr: -0.03%
[DCF] Terminal Value 73.68% ; FCFF base≈8.50b ; Y1≈7.69b ; Y5≈6.62b
[DCF] Fair Price = 49.85 (EV 105b - Net Debt 28.1b = Equity 77.3b / Shares 1.55b; r=8.35% [WACC [floored]]; 5y FCF grow -11.70% → 2.50% )
EPS Correlation: 95.11 | EPS CAGR: 10.46% | SUE: 0.29 | # QB: 0
Revenue Correlation: 99.23 | Revenue CAGR: 12.92% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.27 | Chg30d=+0.20% | Revisions=+25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=1.31 | Chg30d=-0.24% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=8.13 | Chg30d=+18.49% | Revisions=-40% | GrowthEPS=+77.6% | GrowthRev=+7.6%
EPS next Year (2027-12-31): EPS=9.27 | Chg30d=+15.29% | Revisions=-40% | GrowthEPS=+14.0% | GrowthRev=+5.7%
[Analyst] Revisions Ratio: -44% (up=1, down=5)